# Mechanism of Action Class Usage

Generated on 2025-10-19 from `src/data/articles.json`. Each mechanism string was split on semicolons and trimmed before counting.

Note: mechanism labels retain the casing found in the source data, so similar classes with different capitalization appear separately.

## Ranked classes

1. **5-HT2A receptor agonist** — 75 articles
2. **NMDA receptor antagonist** — 51 articles
3. **Gamma-aminobutyric acid type A receptor positive allosteric modulator (benzodiazepine site)** — 50 articles
4. **Dopamine-norepinephrine reuptake inhibitor** — 48 articles
5. **Dopamine-norepinephrine releasing agent** — 28 articles
6. **Serotonin-dopamine-norepinephrine releasing agent** — 24 articles
7. **Dopamine-norepinephrine reuptake inhibitor (potent)** — 21 articles
8. **μ-Opioid receptor agonist (full)** — 21 articles
9. **5-HT2A receptor agonist (potent)** — 17 articles
10. **5-HT2B receptor agonist (cardiotoxic)** — 17 articles
11. **5-HT2A receptor partial agonist** — 16 articles
12. **Serotonin releasing agent** — 16 articles
13. **Stimulant (uncertain mechanism)** — 15 articles
14. **CB1 and CB2 receptor full agonist** — 14 articles
15. **serotonin reuptake inhibitor** — 12 articles
16. **μ-Opioid receptor agonist** — 12 articles
17. **Gamma-aminobutyric acid type B receptor agonist** — 9 articles
18. **Monoamine oxidase inhibitor** — 8 articles
19. **prodrug of LSD** — 8 articles
20. **5-HT2C receptor agonist** — 7 articles
21. **Muscarinic acetylcholine receptor antagonist** — 7 articles
22. **AMPA receptor positive allosteric modulator** — 6 articles
23. **Dopamine reuptake inhibitor** — 6 articles
24. **Multi-target modulator** — 6 articles
25. **Serotonin-dopamine-norepinephrine reuptake inhibitor** — 6 articles
26. **5-HT2C receptor partial agonist** — 5 articles
27. **Atypical dopamine reuptake inhibitor** — 5 articles
28. **Gamma-aminobutyric acid type A receptor positive allosteric modulator (non-benzodiazepine site)** — 5 articles
29. **Multiple receptor antagonist** — 5 articles
30. **κ-opioid receptor antagonist** — 5 articles
31. **G-protein-biased μ-opioid receptor agonist (partial)** — 4 articles
32. **Gamma-aminobutyric acid type A receptor agonist (at high concentration)** — 4 articles
33. **Gamma-aminobutyric acid type A receptor positive allosteric modulator** — 4 articles
34. **Gamma-hydroxybutyrate receptor agonist** — 4 articles
35. **Mu-opioid receptor agonist** — 4 articles
36. **Norepinephrine reuptake inhibitor** — 4 articles
37. **Voltage-gated calcium channel alpha-2-delta subunit ligand** — 4 articles
38. **δ-opioid receptor antagonist** — 4 articles
39. **5-HT2B receptor agonist** — 3 articles
40. **5-HT2B receptor partial agonist** — 3 articles
41. **CB1 and CB2 receptor partial agonist** — 3 articles
42. **Kappa-opioid receptor agonist** — 3 articles
43. **Monoamine oxidase B inhibitor** — 3 articles
44. **Serotonin reuptake and receptor modulators** — 3 articles
45. **serotonin-norepinephrine reuptake inhibitor** — 3 articles
46. **5-HT1A receptor preferring agonist** — 2 articles
47. **5-HT2A receptor agonist (partial)** — 2 articles
48. **5-HT2A receptor full agonist** — 2 articles
49. **5-HT2C partial agonist** — 2 articles
50. **Combination mechanism** — 2 articles
51. **Competitive antagonist at muscarinic acetylcholine receptors M1 and M2 (anticholinergic)** — 2 articles
52. **Cytochrome P450 3A4 inhibitor** — 2 articles
53. **G-protein-biased μ-opioid receptor agonists** — 2 articles
54. **Gamma-aminobutyric acid type A receptor agonist** — 2 articles
55. **Glutathione precursor** — 2 articles
56. **H1 histamine receptor inverse agonist** — 2 articles
57. **Imidazoline receptor agonist** — 2 articles
58. **Indirect adrenergic agonist** — 2 articles
59. **kappa-opioid receptor agonist (weak)** — 2 articles
60. **Norepinephrine-dopamine reuptake inhibitor (NDRI)** — 2 articles
61. **prodrug of morphine** — 2 articles
62. **Serotonin receptor agonist** — 2 articles
63. **serotonin releasing agent (weak)** — 2 articles
64. **Serotonin-norepinephrine-dopamine releasing agent (SNDRA)** — 2 articles
65. **sodium channel blockade** — 2 articles
66. **Trace amine receptor agonist** — 2 articles
67. **voltage-gated potassium channel blockade** — 2 articles
68. **weak serotonin reuptake inhibition** — 2 articles
69. **weak serotonin reuptake inhibitor** — 2 articles
70. **μ-Opioid receptor agonist (limited data)** — 2 articles
71. **5-HT1A receptor agonist** — 1 article
72. **5-HT1A receptor agonist (high affinity)** — 1 article
73. **5-HT1A receptor agonist (psilocin acts as prodrug)** — 1 article
74. **5-HT1A receptor agonist (strongest binding affinity)** — 1 article
75. **5-HT1A receptor full agonist** — 1 article
76. **5-HT1A receptor partial agonist** — 1 article
77. **5-HT2A receptor agonist (DMT component)** — 1 article
78. **5-HT2A receptor agonist (potent, pEC50 9.43)** — 1 article
79. **5-HT2A receptor agonist (primary)** — 1 article
80. **5-HT2A receptor antagonist** — 1 article
81. **5-HT2A receptor partial agonist (5-8 times greater affinity than mescaline)** — 1 article
82. **5-HT2A receptor partial agonist (low potency)** — 1 article
83. **5-HT2A receptor partial agonist (prodrug of 4-HO-MiPT)** — 1 article
84. **5-HT2A receptor partial agonist (weak)** — 1 article
85. **5-HT2B receptor partial agonist (moderate-efficacy)** — 1 article
86. **5-HT2C receptor agonist (pKi 7.8)** — 1 article
87. **5-HT2C receptor full agonist** — 1 article
88. **5-HT2C receptor partial agonist (high-efficacy)** — 1 article
89. **5-HT6 receptor agonist** — 1 article
90. **Acetylcholine precursor** — 1 article
91. **Acetylcholinesterase inhibitor** — 1 article
92. **Activates phospholipase A2 instead of phospholipase C** — 1 article
93. **active metabolite of tramadol** — 1 article
94. **acts as prodrug for LSD via deacylation** — 1 article
95. **Adenosine receptor antagonist** — 1 article
96. **Adenosine receptor antagonist (competitive inhibitor)** — 1 article
97. **adrenergic alpha-1 receptor agonist** — 1 article
98. **Adrenergic receptor agonist** — 1 article
99. **affects dopamine, acetylcholine, and serotonin receptors** — 1 article
100. **AMPA glutamate receptor antagonist** — 1 article
101. **AMPA receptor modulator (via glutathione)** — 1 article
102. **Androgen receptor agonist** — 1 article
103. **anti-parkinsonian** — 1 article
104. **approximately 1.85 times more selective for norepinephrine than dopamine** — 1 article
105. **Aromatase inhibitor** — 1 article
106. **at high doses affects norepinephrine receptors** — 1 article
107. **Beta-adrenergic receptor antagonists** — 1 article
108. **blocks dopamine transporter (DAT IC50: 0.79 nM)** — 1 article
109. **blocks norepinephrine transporter (NET IC50: 17.96 nM)** — 1 article
110. **blocks serotonin transporter (SERT IC50: 3.13 nM)** — 1 article
111. **CB1 cannabinoid receptor full agonist (Ki 0.9 nM, EC50 1.8 nM)** — 1 article
112. **CB1 cannabinoid receptor full agonist (Ki 5.84 nM)** — 1 article
113. **CB1 receptor full agonist** — 1 article
114. **CB2 cannabinoid receptor full agonist (Ki 23.2 nM, EC50 3.2 nM) with selectivity for CB2** — 1 article
115. **CB2 cannabinoid receptor full agonist (Ki 4.57 nM, with slight selectivity)** — 1 article
116. **CB2 receptor full agonist (5x lower affinity than CB1)** — 1 article
117. **Central nervous system depressant** — 1 article
118. **converts nicotinamide to N-methyl-nicotinamide** — 1 article
119. **converts to dopamine, norepinephrine, and epinephrine (catecholamines)** — 1 article
120. **Cystine-glutamate antiporter substrate** — 1 article
121. **cytidine converts to uridine enhancing phosphatidylcholine synthesis** — 1 article
122. **D2 dopamine receptor agonist (weak)** — 1 article
123. **D2 receptor agonist (through LSD metabolite)** — 1 article
124. **Deliriant (uncertain mechanism)** — 1 article
125. **delta-opioid receptor agonist (weak)** — 1 article
126. **DMAE is converted to choline which serves as a precursor for acetylcholine synthesis** — 1 article
127. **does not bind to monoamine transporters** — 1 article
128. **dopamine D1, D2, D3, D4, D5 receptor binding (lower affinity)** — 1 article
129. **Dopamine receptor agonist** — 1 article
130. **Dopamine releaser** — 1 article
131. **dopamine releaser and reuptake inhibitor** — 1 article
132. **Dopamine releasing agent and reuptake inhibitor** — 1 article
133. **dopamine reuptake inhibitor (weak)** — 1 article
134. **dopamine reuptake inhibitor and releaser** — 1 article
135. **Dopamine synthesis enhancer** — 1 article
136. **dopamine transporter phosphorylation (increases extracellular dopamine)** — 1 article
137. **dopamine-noradrenaline reuptake inhibitor** — 1 article
138. **Enhanced high-affinity choline uptake (HACU) in the hippocampus** — 1 article
139. **enhances acetylcholine synthesis via cholinergic pathways** — 1 article
140. **enhances GABA efficiency and effects** — 1 article
141. **Estrogen receptor agonist** — 1 article
142. **facilitates trimethylamine (betaine) production for osmoregulation and SAM-e synthesis** — 1 article
143. **Full agonist at benzodiazepine/GABA-A receptor** — 1 article
144. **GABA-A receptor positive allosteric modulator** — 1 article
145. **GABA-A receptor positive allosteric modulator (binds to proconvulsant site)** — 1 article
146. **GABA-A receptor positive allosteric modulator (increases frequency of chloride channel opening)** — 1 article
147. **GABA-A receptor positive allosteric modulator (preferential affinity for alpha-1, alpha-3, and alpha-5 subunits)** — 1 article
148. **GABA-A receptor potentiation** — 1 article
149. **GABAA receptor positive allosteric modulator (binds to barbiturate site, increases chloride ion pore opening duration)** — 1 article
150. **GABAA receptor positive allosteric modulator (binds to distinct site from benzodiazepines)** — 1 article
151. **Gamma-aminobutyric acid type A receptor agonist (stereoselective)** — 1 article
152. **Glutamate receptor modulator** — 1 article
153. **glycine receptor potentiation** — 1 article
154. **H1 histamine receptor antagonist** — 1 article
155. **H1 histamine receptor antagonist via promethazine** — 1 article
156. **Histamine H1 receptor antagonist** — 1 article
157. **increased acetylcholine synthesis** — 1 article
158. **increased nitric oxide activity (cerebral blood flow enhancement)** — 1 article
159. **increases acetylcholine synthesis and release via enhanced choline availability** — 1 article
160. **increases chloride channel opening frequency when GABA is present** — 1 article
161. **increases dopamine and norepinephrine levels in CNS** — 1 article
162. **increases duration of chloride ion channel opening** — 1 article
163. **increases serotonin, dopamine, and norepinephrine activity** — 1 article
164. **may inhibit MAO-A and MAO-B** — 1 article
165. **mechanism underlying hallucinogenic effects remains unstudied** — 1 article
166. **Melatonin receptor agonist** — 1 article
167. **metabolized by CYP2D6 and CYP3A4** — 1 article
168. **Metabolizes into DMAE and pCPA** — 1 article
169. **Metabolizes to choline and cytidine** — 1 article
170. **Metabotropic glutamate receptor agonist** — 1 article
171. **Methyl group donor in neurotransmitter synthesis** — 1 article
172. **mGluR2/3 receptor agonist (indirect)** — 1 article
173. **minimal serotonin activity** — 1 article
174. **minor norepinephrine releasing agent** — 1 article
175. **monoamine releasing agent** — 1 article
176. **Monoamine triple reuptake inhibitor (dopamine, norepinephrine, serotonin)** — 1 article
177. **Mood stabilizer** — 1 article
178. **Mu-opioid receptor agonist (as morphine after first-pass metabolism)** — 1 article
179. **Mu-opioid receptor agonist (highly selective)** — 1 article
180. **mu-opioid receptor agonist (selective)** — 1 article
181. **Mu-opioid receptor agonist (via active metabolite morphine)** — 1 article
182. **Mu-opioid receptor agonists** — 1 article
183. **Muscarinic acetylcholine receptor agonist** — 1 article
184. **N-methyl-D-aspartate receptor agonist** — 1 article
185. **nACh receptor antagonist (beta2-subunit)** — 1 article
186. **NF-kB inhibitor** — 1 article
187. **Nicotinic acetylcholine receptor agonist** — 1 article
188. **NMDA receptor antagonist (noncompetitive)** — 1 article
189. **NMDA receptor antagonist (primary)** — 1 article
190. **NMDA receptor antagonist (selective ligand without appreciable dopamine transporter affinity)** — 1 article
191. **NMDA receptor modulator (via glutathione)** — 1 article
192. **Nociceptin receptor agonist with μ-opioid receptor affinity** — 1 article
193. **Nootropic (uncertain mechanism)** — 1 article
194. **norepinephrine releaser** — 1 article
195. **norepinephrine releaser and reuptake inhibitor** — 1 article
196. **Norepinephrine releasing agent** — 1 article
197. **Norepinephrine releasing agent and reuptake inhibitor** — 1 article
198. **Norepinephrine reuptake inhibitor (likely triple monoamine reuptake inhibitor)** — 1 article
199. **norepinephrine reuptake inhibitor (metabolite norpethidine is a serotonin reuptake inhibitor)** — 1 article
200. **norepinephrine reuptake inhibitor (weak)** — 1 article
201. **norepinephrine reuptake inhibitor and releaser** — 1 article
202. **Opioid receptor agonist (limited data)** — 1 article
203. **possible 5-HT2A receptor agonist (speculated)** — 1 article
204. **Possible CB1 cannabinoid receptor agonist (speculated)** — 1 article
205. **possible monoamine oxidase inhibition** — 1 article
206. **Potassium channel opener** — 1 article
207. **potent MAO-A inhibitor (IC50 400 nM)** — 1 article
208. **potent nicotinic acetylcholine antagonist** — 1 article
209. **potent reversible MAO-A inhibitor (IC50 ~1700 nM)** — 1 article
210. **potential MAOI properties** — 1 article
211. **Precursor to choline and glycerophosphate in the brain** — 1 article
212. **Precursor to L-DOPA** — 1 article
213. **prodrug metabolized by CYP2D6 to morphine** — 1 article
214. **prodrug of 6-monoacetylmorphine** — 1 article
215. **prodrug of dihydromorphine** — 1 article
216. **prodrug of levorphanol** — 1 article
217. **prodrug of morphine via codiene** — 1 article
218. **prodrug of O-desmethyltramadol** — 1 article
219. **prodrug of psilocin** — 1 article
220. **prodrug of R-4618** — 1 article
221. **Prodrug to muscimol (gamma-aminobutyric acid type A receptor agonist)** — 1 article
222. **prostaglandin synthetase inhibitor** — 1 article
223. **releases phosphate to regenerate ATP during periods of stress or high-intensity exercise** — 1 article
224. **reversible monoamine oxidase-A inhibitor (harmala alkaloids)** — 1 article
225. **Selective serotonin releasing agent (SSRA)** — 1 article
226. **selective serotonin reuptake inhibitor (SSRI)** — 1 article
227. **Serotonin 5-HT3 receptor antagonist** — 1 article
228. **Serotonin receptor agonist (partial)** — 1 article
229. **serotonin releaser** — 1 article
230. **Serotonin releaser and reuptake inhibitor** — 1 article
231. **Serotonin releasing agent and reuptake inhibitor** — 1 article
232. **Serotonin reuptake inhibitor (weak)** — 1 article
233. **Serotonin reuptake inhibitor and releaser** — 1 article
234. **Serotonin-norepinephrine releasing agent (SNRA)** — 1 article
235. **Serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI)** — 1 article
236. **sigma receptor agonist** — 1 article
237. **Sigma-1 receptor agonist** — 1 article
238. **Sodium channel blockers** — 1 article
239. **stimulates glutathione synthesis** — 1 article
240. **Stores high-energy phosphate groups as phosphocreatine (creatine phosphate)** — 1 article
241. **supports catecholamine neurotransmitter synthesis** — 1 article
242. **supports phospholipid biosynthesis and cell membrane integrity** — 1 article
243. **supports phospholipid synthesis for cell membrane structure** — 1 article
244. **suspected mu-opioid receptor affinity** — 1 article
245. **TAAR1 agonist** — 1 article
246. **to a lesser extent affects epinephrine, glutamate, and cortisol** — 1 article
247. **two-pore-domain K+ channel activation** — 1 article
248. **Uncertain mechanism** — 1 article
249. **VMAT2 inhibitor** — 1 article
250. **weak dopamine releaser** — 1 article
251. **weak monoamine oxidase inhibitor** — 1 article
252. **κ-Opioid receptor agonist** — 1 article
253. **μ-Opioid receptor agonist (partial)** — 1 article
254. **μ-Opioid receptor agonist (peripherally-restricted)** — 1 article
255. **μ-opioid receptor antagonist** — 1 article
